2024.12.04
JAK1/2 Inhibitor Ruxolitinib for the Treatment of Systemic Chronic Active Epstein-Barr Virus Disease: A Phase II Study, Masataka Ishimura, Department of Perinatal and Pediatric Medicine
Lecturer Masataka Ishimura has published their research results.
DOI:doi.org/10.1016/j.bneo.2024.100053
Journal: Blood neoplasia
Title: JAK1/2 Inhibitor Ruxolitinib for the Treatment of Systemic Chronic Active Epstein-Barr Virus Disease: A Phase II Study
Authors: Yu Uemura, Masahide Yamamoto, Masataka Ishimura, Hirokazu Kanegane, Akihisa Sawada, Akihiro Hirakawa, Ken-Ichi Imadome, Mayumi Yoshimori, Masashi Nagata, Kouhei Yamamoto, Norio Shimizu, Ryuji Koike, Ayako Arai
For more information, please see below.Title: JAK1/2 Inhibitor Ruxolitinib for the Treatment of Systemic Chronic Active Epstein-Barr Virus Disease: A Phase II Study
Authors: Yu Uemura, Masahide Yamamoto, Masataka Ishimura, Hirokazu Kanegane, Akihisa Sawada, Akihiro Hirakawa, Ken-Ichi Imadome, Mayumi Yoshimori, Masashi Nagata, Kouhei Yamamoto, Norio Shimizu, Ryuji Koike, Ayako Arai
DOI:doi.org/10.1016/j.bneo.2024.100053